Bonus Shares Incoming! Dr. Lal PathLabs Makes It Official; Key Dates Inside For 1:1 Bonus Issue Purpose

Dr. Lal PathLabs has set the record date for its much-anticipated bonus share offering, a significant corporate move that may thrill its investors. With a market capitalization of 24,067.87 Cr, Dr. Lal PathLabs' shares closed at Rs 2872.90 each on the BSE on Friday, December 12. The healthcare stock hit a 52-week high of Rs 3,542.60 on 19/09/2025, and a 52-week low of Rs 2,295.10 on March 3, 2025.

Dr. Lal PathLabs Bonus Issue Record Date

On December 8, 2025, the company notified the stock exchanges that its Board of members approved issuing bonus equity shares in a 1:1 ratio, meaning that each eligible member whose name appears in the Register of Members of the Company/List of Beneficial Owners as received from the National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) as on the "Record Date" to be determined by the Board for this purpose would receive one new fully paid-up equity shares of face value of Rs 10/- each.

"In this regard, we wish to inform you that the Board of Directors today i.e. December 12, 2025, through Circular Resolution fixed "Friday, December 19, 2025" as the Record Date for the purpose of determining the eligibility of the Members of the Company for issuing bonus equity shares. Further, in accordance with SEBI circular no. CIR/CFD/PoD/2024/122 dated September 16, 2024, the deemed date of allotment of bonus equity shares shall be "Monday, December 22, 2025," said Dr. Lal PathLabs in a stock exchange filing.

Dr. Lal PathLabs Bonus Issue Details

The company would issue 8,37,75,510 bonus equity shares, or Rs 83.77 crore, as part of this bonus issue. A total of Rs 83,77,55,100 would be withdrawn from the Securities Premium Account in order to implement this bonus issue. The projected date by which Dr. Lal Pathlabs will credit or allocate such bonus shares to the eligible shareholders is December 30, 2025, or within two months of the Board of Directors' approval date.

Dr. Lal PathLabs Share Price Analysis

As of December 12, 2025, Trendlyne's technical analysis for Dr. Lal PathLabs Ltd. (LALPATHLAB) indicates a mixed but leaning negative sentiment for the stock, which is currently classified as a "Mid-range Performer." The price, which is currently trading at Rs 2874.50, is below both its 200-day Simple Moving Average (SMA) of Rs 2,948.1 and its 50-day SMA of Rs 3,096.2, which are key technical indicators of weakness in the medium-to-long term trend.

Although the Relative Strength Index (RSI) is considered to be in the mid-range at 31.5, the stock's Money Flow Index (MFI) is in the oversold region at 20.3, indicating recent severe selling pressure, while the 1-year Beta shows extremely low volatility. The stock is still 25.33% higher than its 52-week low price despite these current technical headwinds.

Dr. Lal PathLabs Target Price

"Dr Lal PathLabs is showing steady bullish momentum, holding firmly above its key support zone near Rs 2,800. The stock is forming higher lows on the daily chart, indicating sustained buying interest. A decisive move above Rs 2,900 could trigger further upside toward Rs 3,000, while Rs 2,750 remains an important support level," commented technical analyst Riyank Arora of Mehta Equities Ltd.

"Dr Lal Path Labs is bearish & also extremely oversold with next support at 2742. Investors should buy only if Daily close is above resistance of 2954 could lead to a target of 3309 in the near term," recommended A R Ramachandran, Independent SEBI-registered Research Analyst, Tips2trades.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.